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Summary
The concentration of calcium in the extracellular fluid is crucial
for several physiological functions in humans and in normal
conditions its circulating levels are maintained between 8.5-10.5
mg/dl. Among the regulators of calcium homeostasis parathy-
roid hormone (PTH) acts though the G-protein coupled PTH re-
ceptor and a hormone-sensitive adenylate cyclase, with Gsα
subunit (stimulatory guanine nucleotide-binding protein alpha-
subunit) being responsible for the stimulation of the catalytic
complex. Mutations of the Gsα encoding gene, GNAS1, are
causal for some forms of congenital hypocalcemia. In the pre-
sent study genetic variability in the GNAS1 gene was analyzed
in a group of hypocalcemic patients collected through the Ital-
ian Register of Primary Hypoparathyroidism (RIIP). We identi-
fied a new intronic variant of the GNAS1 gene, consisting of a
T>C polymorphism. This polymorphism was studied in a group
of unrelated healthy subjects for a possible association with
bone turnover biomarkers and bone mineral density. The T>C
polymorphism was found in 18% of the studied populations,
with 15% heterozygous TC and 3% homozygous CC (Pearson χ2
analysis: p=0.04). A significant association with low serum cal-
cium levels was found in healthy subjects carrying the T > C
polymorphism (ANCOVA analysis: p=0.04). These results sup-
port segregation of a novel GNAS1 gene intronic variant with
low calcium levels in primary hypoparathyroidism, pseudo-hy-
poparathyroidism and in the general population.
KEY WORDS: hypocalcemia; GSα Unit; GNAS1 gene; primary hypoparathy-
roidism; pseudo-hypoparathyroidism.
Introduction
Calcium (Ca) is an important bioinorganic ion performing a va-
riety of intra- and extra-cellular functions with an important role
in maintaining normal homeostasis. The concentration of Ca in
the extracellular fluid is crucial for many physiological process-
es, ranging between 8.5 and 10.5 mg/dl (2.25 to 2.6 mmol/L).
The total plasmatic pool of Ca consists of about 35% protein-
bound (mostly albumin-bound), 15% complexed to phosphate
and citrate, and 50% ionized. It is only the ionized form of Ca
that is relevant in several physiological processes, as neuro-
muscular contractility, enzymatic activities, and coagulation (1).
Hypocalcemia is a disorder that can be asymptomatic or pre-
sent as an emergency case (2). Generally it is not congenital,
but more often the result of vitamin D deficiency or neck
surgery. Genes responsible for the hereditary forms include the
Gsα subunit gene (GNAS1) (3, 4), the parathyroid hormone
gene (PTH) (5), the calcium-sensing-receptor gene (CaSR) (6),
and the human orthologue gene of the Drosophila glial cells
missing gene dGCM (GCMB) (7, 8). 
The activity of the hormone-sensitive adenyl cyclase, the en-
zyme that catalyzes the formation of the intracellular second
messenger cyclic AMP (cAMP), is under dual regulation by two
guanine nucleotide-binding proteins (G-proteins) and, of these,
Gsα mediates the action of PTH and cAMP accumulation and
protein phosphorylation (9). The GNAS1 gene is located in the
chromosomal region 20q13.3 and encompasses 13 exons, with
a cDNA sequence spanning a region of about 1.2 Kb and giv-
ing rise to maternally, paternally, or bi-allelically expressed
transcripts (10, 11). Several of the naturally occurring muta-
tions of the GNAS1 gene have been identified through the en-
tire coding region, being responsible of different congenital dis-
orders (3, 12-14). Specific aminoacid substitutions resulting in
constitutive activation of Gsα subunit have been firstly charac-
terized in growth hormone secreting pituitary tumors (15, 16).
In addition, mutations of GNAS1 gene can also lead to a condi-
tion known as McCune-Albright syndrome (MAS; MIM #
174800) (17), characterized by polyostotic fibrous dysplasia,
cafè-au-lait patches on the skin, and endocrine abnormalities
such as hyperthyroidism and precocious puberty. Conversely,
inactivating mutations of GNAS1 gene result in a condition
known as Albright’s Hereditary Osteodystrophy (AHO;MIM #
103580) characterized by short stature, round face with a low
flat nasal bridge, shortening of the fourth and fifth metacarpals
and metatarsals, obesity, and subcutaneous and intracranial
calcification (4). Small insertions/deletions and aminoacid sub-
stitutions represent the predominant type of mutations, but
nonsense and point mutations, leading to altered translation
initiation or aberrant mRNA, have also been documented (18).
Marguet et al. (12) observed that in 51% of PHP-Ia (pseudo-
hypoparathyroidism type Ia) patients GNAS1 gene mutations
were found in hypocalcemic siblings. Conversely, Linglart et al.
(3) did not find GNAS1 mutations in a small number of sporadic
cases with isolated AHO, while GNAS1 gene mutations are
present in subjects within PHP-Ia kindreds where isolated AHO
is present in family members (3).
Recent studies on the GNAS1 locus indicated that this gene is
extremely complex, with multiple alternatively spliced tran-
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scripts encoding multiple protein products. Polymorphic mark-
ers of the GNAS1 gene, currently employed in the genetic eval-
uation of congenital disorders, frequently result to be uninfor-
mative due to the low associated heterozygosity value (19).
Nevertheless, GNAS1 is actually the only gene encoding a G-
protein that has been identified as target for mutations that un-
equivocally cause endocrine disorders, leading to the clinical
phenotype of hormone defect or excess (15, 18-20). Moreover,
the PTH receptor (PTHr) is coupled to G-proteins (21), with a
specific α-subunit being responsible of both receptor and effec-
tors interactions (22). It is, therefore, not surprising that inacti-
vating mutations of the GNAS1 gene have been identified as
responsible of congenital primary hypocalcemia in patients with
PHP and pseudo-PHP (PPHP) (23-26).
The aim of the present study was to evaluate the presence of
GNAS1 gene mutations that have been described in the litera-
ture and of potential new mutations responsible for various
forms of hypocalcemia. In this study, the genetic screening of
primary hypocalcemia made possible the identification of an in-
tronic variant of the GNAS1 gene with statistically significant
polymorphism information content (PIC). This genetic marker
was used to screen a population of 100 healthy volunteers and
described as a new polymorphic site.
Materials and methods
Clinical characteristics of the patients
The Italian Register of Primary Hypoparathyroidism was created
in 1996 in Florence and named RIIP (Registro Italiano
Ipoparatiroidismo Primitivo: www.dmi.unifi.it/ipopara/default.htm).
RIIP collects clinical records both on sporadic and familial cas-
es of primary hypoparathyroidism. Information was obtained
from Italian endocrine, neurological and pediatric Centers
through the compilation of a form, that includes the identifica-
tion code of the patient, the date of birth, the diagnosis of the
type of hypoparathyroidism, the presence of other associated
diseases (typical or not), data on organ and non-organ antibod-
ies, and results of PTH infusion test. Each subject is requested
to give informed consent and at any time the patient can ask to
obtain his/her clinical data deleted from the official file. The pri-
mary goal is represented by collection of clinical information to
obtain epidemiological data on primary hypoparathyroidism in
Italy. The Register supports also the genetic test for Centers
not equipped for molecular diagnostic procedures.
At present, 107 Caucasian hypocalcemic patients (61 males
and 46 females, age range 6-71 yrs, mean age 42 ± 15 SEM
yrs) have been registered in the RIIP.
Registered subjects encompassed 14 cases of PHP Ia, 8 cas-
es of PHP Ib, 8 cases of PPHP, 57 cases of idiopathic primary
hypocalcemia, 2 cases of DiGeorge syndrome, 8 cases of iso-
lated parathyroid agenesis, and 10 case of Autoimmune Polyg-
landular Syndrome (APS) type 1. Among the 107 subjects, 39
patients, affected by clinically idiopathic hypocalcemia or by
PHP (10 women and 29 men; age range 7-66 yrs, mean age
40 ± 22.4 SEM yrs) and 7 relatives, underwent genetic test to
evaluate the presence of GNAS1 gene mutations. Develop-
mental status of the patients was appropriate. In all the sub-
jects routine exams, serum Ca (corrected for levels of serum
albumin), phosphorus, magnesium, bone alkaline phos-
phatase, PTH, vitamin D (25OH2D3 and 1-25OH2D3), organ-
and non-organ specific antibodies, TSH, fT3, fT4, FSH, and LH
were evaluated. A 24 hrs urinary sample was collected in order
to measure the excretion of calcium, phosphorus, magnesium,
deoxypiridinoline, and cAMP. Lumbar spine- and femoral-BMD
(LS-BMD and F-BMD) measured by DXA (Hologic QDR 4500),
electrocardiogram, electromyography, ocular inspection, and
skull X-ray and/or Computed Tomography were performed in
all patients. 
A population of Caucasian healthy volunteers from the Flo-
rence metropolitan area was recruited by mailing. The group
was composed by 75 women and 25 men with an age of 47-76
yrs and a mean age (± SEM) of 57 ± 8 yrs. A large database
was completed for all subjects with inclusion of a detailed med-
ical history and of dietary Ca intake assessed by a sequential
self-questionnaire that included foods accounting for the major-
ity of Ca in the diet. 
The Ethical Committee of the University of Florence approved
the study and both patients and normal volunteers were re-
quested to give informed consent for genetic evaluation.
Genetic analysis of the GNAS1 gene
Genomic DNA was isolated from peripheral EDTA blood sam-
ples of the hypocalcemic and healthy population with the phe-
nol/chloroform procedure. Exons 1-13 of the GNAS1 gene
were amplified in 50 ml by PCR (polymerase chain reaction)
containing 67 mM Tris-HCl, 16.6 mM (NH4)2SO4, 5 mM MgCl2,
0.01% Tween-20, 200 µM each of the four deoxyribonu-
cleotides, 0.4 µM of oligonucloetide primers and 1 U of Polytaq
(Polymed, Florence, Italy) (23). The length of the PCR products
was analyzed on 3% agarose gels, stained with ethidium bro-
mide and visualized with UV light. In Table I are reported the
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Table I - DNA sequences of the oligonucleotide primers used to amplify exons of the GNAS1 gene.
Exon Upper primer Lower primer Annealing 
temperature 
(°C)
1 5’-ATGGGCTGCCTCGGGAACAGTA-3’ 5’-CCCTTACCCAGCAGCAGCAGGC-3’ 58
2 5’-AAAATGCCTCCTTCATAACCTGA-3’ 5’-GCCCACCTATACTTCCTAAAG-3’ 55
3 5’-ATGGTTGAGGAATGTAGAGAGACTG -3’ 5’-CAGTATGATCTTCATGTTTGTTTG-3’ 55
4-5 5’-ATGAAAGCAGTACTCCTAACTGA-3’ 5’-TGGATGCTCCTGCCCATGTG-3’ 66
6 5’-ATTAGTTCAAGCTCTTGCCTTTC-3’ 5’-TTGTCTGTTTTATGTGCTGATGG-3’ 60
7-8 5’-TGCTGCATAACTGTGGGACG-3’ 5’-AGAAACCATGATCTCTGTTATA-3’ 60
9-11 5’-ACAGAGATCATGGTTTCTTG-3’ 5’-AGAACCACCGCAATGAACAGCC-3’ 60
12 5’-AGACTTCACGAGCTACAGAGA-3’ 5’-AGAGGAGGAACAAGAGAGGAA-3’ 60
13 5’-CATCAGAGGCTGGCTGACAGCG-3’ 5’-AAGGCTTTAATTAAATTTGGG-3’ 60
From Ref. 19 with minor modifications. 
sequences of the oligonucleotide primers used to amplify ex-
ons of the GNAS1 gene. In each subject both strands of each
exon were sequenced. Sequencing of the PCR products using
both sense and antisense primers was performed using Ampli-
Taq BigDye Terminator kit and 3,100 Genetic Analyzer (Ap-
plied Biosystems). 
Statistical analysis
Pearson chi-square (χ2) analysis was performed to evaluate
the distribution of the genotypes in the population. ANOVA and
ANCOVA analysis were performed and p < 0.05 was accepted
as the value of significance. In order to know which means
contributed to the effect, that is, which groups were particularly
different from others, we performed post hoc LSD (least signifi-
cant difference) test. The results were presented as mean ±
SEM. P < 0.05 was accepted as the value of significance. The
following covariates were considered for the ANCOVA analy-
sis: age, weight, and Ca intake. All statistical tests were per-
formed using Statistica 5.1 Program (Statsoft Inc., Tulsa, OK,
USA).
Results
Direct sequencing of the amplified genomic DNA fragment
showed a novel heterozygous T > C variant at the nucleotide
position 433-18 (intron 5) in 7 of the 39 hypocalcemic patients
and 4 relatives [reference sequence is the Gs-alpha 1 cDNA
(Gene Bank association number SEG-HUMGNAS)] (Figs. 1 A
and C). The T > C transition was present in 18% of the sub-
jects indicated by A, B, C, D1, D2, D3, E1, F1, F2, G1, G2 and
it was not associated with modifications of restriction endonu-
clease recognition sequences. The clinical characteristics of
patients and their first-degree relatives are summarized in
Table II. No subject with the exon 7 polymorphism already de-
scribed in the literature (15) has been detected in our study. Of
the 39 subjects analyzed, 13 had the polymorphism at the exon
5 previously described by Miric et al. (9), two being homozy-
gous. In family D, the patient affected (D1) and his sons (D2
and D3) showed the heterozygous T > C mutation and no mu-
tations were found in the mother (D4). Patient D2 had a poly-
morphism at the exon 13 together with the T > C polymorphism
at the intron 5 (27). In family F, patient (F1) and her mother
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Figure 1 - A: Direct DNA sequencing analysis of GNAS1 gene. The figure shows the A → G substitution at the intron 5 nucleotide position 433-18 [ref-
erence sequence is the Gs-alpha 1 cDNA (Gene Bank association number SEG.HUMGNAS)]. Right: sequencing analysis in subjects with the T > C
polymorphic site. Left: sequencing analysis in subject without the T>C polymorphic site. B: The Table indicates the distribution of the T > C polymor-
phism in the 100 Caucasian unrelated subjects. The T > C polymorphism was found in 18% of the population [3% homozygous (CC) and 15% het-
erozygous (TC)]. Pearson χ2 analysis: df = 2; p = 0.04. The TT genotype was present in 82 subjects (82%) of the population with the distribution be-
tween females and males respectively of 64 females (78.05%) vs. 18 males (21.95%). The CC was present in 3 female subjects (3%) of the total pop-
ulation while the TC genotype was present in 15 subjects (15%) of the total population with a distribution between females and males respectively of
7 females (46.67%) and 8 males (53.33%). C: Schematic representation of GNAS1 with the location of the polymorphic sites. The T > C polymorphic
site has been localized at the intron 5 nucleotide position 433-18 [reference sequence is the Gs.alpha.1 cDNA (Gene Bank association number
SEG.HUMGNAS)]. The Table indicates a schematic representation of the polymorphic sites described in the literature and of the new one.
A B
C
(F2) carried out the T > C mutation with no mutations found in
the father (F3). In family G patient (G1) and his brother (G2)
carried out the T > C mutation with no mutations found in the
mother. DNA from the G1 patient father was not available. 
In addition, constitutional DNA from a population of 100 (200
chromosomes) unrelated Caucasian individuals (75 females
and 25 males) who had no known history of hypocalcemia
was amplified by PCR and sequenced to verify the frequency
of the T > C variant. The clinical characteristics of the study
population are reported in Table III and the allele distribution
of the GNAS1 gene polymorphism in this population is shown
in Table IV. The T allele had a frequency of 0.895 and the C
allele had a frequency of 0.105. The χ2 test was 1.24 with 1
degree of freedom. From Hartl table (28) we observed that
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Table II - Clnical and biochemical data of the hypocalcemic patients.
Code Sex Age S-Ca UrCa s-P PTH TSH Diagnosis and Imaging GNAS1 gene
# (Yr) (8.5-10.5 (100-300 (2.8-4.5 (10-60 (0.25-3.5 clinical signs polymorphism
mg/dl)* mg/24h) mg/dl) ng/ml) mU/ml)
A1 F 65 06.8 362 4.80 026 < 0.05 Late idiopathic hypocalcemic crisis IC Heterozygous
Hyperthyroidism
B1 F 59 NA NA 3.80 099 NA Late idiopathic hypocalcemic crisis IC Heterozygous
C1 M 66 07.7 244 3.80 045 NA Late idiopathic hypocalcemic crisis IC Heterozygous
D1 M 47 05.9 235 4.68 137 3.6 PHP Ib, Subclinical hypothyroidism IC Heterozygous 
Cataract, Br
D2 (S) M 15 09.8 200 4.70 42.3 NA N NA Heterozygous
D3 (S) M 17 09.7 230 4.50 058 NA N NA Heterozygous
D4 (W) F 45 10.1 245 3.50 062 NA N NA NP
E1 M 48 NA NA NA NA NA Late idiopathic hypocalcemic crisis NA Heterozygous
F1 F 07 07.9 288 4.50 143 6.64 PHP Ia , Br, Ob, RF, SC SM Heterozygous
F2 (M) F 36 100. 160 3.90 040 NA Br NA Heterozygous
F3 (F) M 50 09.8 185 3.50 065 NA N NA NP
G1 M 17 08.2 180 4.20 056 2.9 Br, Osteopenia, Hyperprolactinemia, SM NA Heterozygous
G2 (B) M 21 09.6 213 3.90 057 NA N NA Heterozygous
G3 (M) F 62 09.5 228 2.90 060 NA N NA NP
# Proband: bold characters
* Serum Ca levels were corrected for levels of albumin.
Abbreviations: F: Female; M: Male; Br: Brachidactily; IC: Intracranic Calcification; N: Normal; NA: Not Available; Ob: Obesity; NP: Not Polymorphism; PHP:
Pseudohypoparathyroidism; RF: Round Face; SC: Subcutaneous Calcification; SM: Shortening of Metacarpals; (S): Son; (W): Wife; (M): Mother; (F): Father;
(B): Brother.
Table III - Clinical characteristics of the healthy population.
Genotype TT TC CC
Number 82 15 3
Sex M: 18 M: 7 M: 0
F: 64 F: 8 F: 3
Age (yrs) 56.1 ± 7 57.2 ± 7.9 51 ± 9.1
Dietary Ca intake (mg/day) 797 ± 320 801 ± 263 811 ± 296
LS-BMD (g/cm2) M: 0.896 ± 0.13 M: 0.932 ± 0.13 M: 0.916 ± 0.14
F: 0.826 ± 0.15 F: 0.829 ± 0.4 F: 0.880 ± 0.3
FN-BMD (g/cm2) M: 0.786 ± 0.13 M: 0.770 ± 0.13 M: 0.779 ± 0.12
F: 0.650 ± 0.5 F: 0.690 ± 0.4 F: 0.680 ± 0.5
Height (cm) M: 170 ± 8.4 M: 169.8 ± 6.4 M: 0.779 ± 0.12
F: 160 ± 2.3 F: 162.9 ± 2.6 F: 161.2 ± 1.8
Weight (kg) M: 76 ± 10.4 M: 75.8 ± 6.3 M: 75 ± 8.9
F: 63 ± 2.3 F: 62.9 ± 2.7 F: 63.5 ± 1.7
Serum Ca (mg/dl) 9.1 ± 0.9 8.3 ± 0.87* 8.1 ± 0.25**
PTH (ng/ml) 54 ± 8.1 65 ± 7 67 ± 5
Abbreviations: M: male; F: female; LS-BMD: Lumbar Spine BMD; FN-BMD: Femoral Neck BMD; P values: *TT genotype vs. TC genotype: p=0.03. **TT geno-
type vs. CC genotype p=0.04.
the p value was 0.35 which is greater than 0.05. For this rea-
son genotype frequencies could be considered in Hardy-
Weinberg equilibrium (28, 29). Among a total of 200 indepen-
dent chromosomes examined for the T > C polymorphism,
179 (89.5%) contained the T allele (164 TT and 15 TC geno-
types) and 21 (10.5%) the C allele (15 TC and 6 CC geno-
types). If used for linkage analysis, this polymorphism may be
informative in 18% of cases (2 x 0.895 x 0.105). The T > C
PIC (polymorphism information content) value at the GNAS1
gene was 0.17 (30) and can, therefore, be considered useful
as a genetic marker (www.biosci. ohio.state. edu).
The T > C polymorphism was found in 18% of the healthy Cau-
casian population with 3% homozygous and 15% heterozy-
gous (Fig. 1B). There were three genotype groups and by
Pearson χ2 analysis we observed: 82 (82%) homozygous TT
[64 (78.05%) females vs. 18 (21.95%) males], 15 (15%) het-
erozygous TC [7 (46.6%) females vs. 8 (53.3%) males], and 3
(3%) homozygous CC [3 (100%) females] (Pearson χ2 analy-
sis: df = 2; p = 0.04) (Fig. 1 B).
Applying ANCOVA analysis to evaluate potential relationships
between GNAS1 genotype and bone biomarkers, we observed
that subjects with T > C polymorphism showed a significant
lower serum Ca (ANCOVA analysis: p = 0.04) than subjects
without this polymorphism. In particular, patients with TC and
CC genotypes had respectively 8.79% and 10.98% lower
serum Ca level in comparison with those with TT genotype [8.3
± 0.87 and 8.1 ± 0.25 vs. 9.1 ± 0.9 mg/dl, p = 0.03 and p =
0.04, respectively] (Fig. 2). No statistically significant differ-
ences were found neither between genotypes and other bio-
chemical markers nor between genotypes and LS and F-BMD
(data not shown).
Discussion
It has been well established that proteins involved in signal
transduction are targets for mutations resulting in human dis-
eases. The identification of mutations of G-proteins had major
implications for understanding the structure and function of
these signaling proteins (2, 14-15, 20-22). By direct DNA se-
quencing we analyzed the entire GNAS1 gene coding se-
quence and identified a novel T > C transition polymorphism
within intron 5. The novel polymorphism was evaluated in a
population of 39 primary hypocalcemic patients and in 100 un-
related healthy subjects. Eighteen percent either of the
hypocalcemic patients or the 100 unrelated subjects carried out
the GNAS1 gene T > C polymorphism. Interestingly, in the lat-
ter group of subjects the GNAS1 gene T > C polymorphism
was significantly associated with lower serum Ca levels when
compared to the negative cases. A number of observations de-
rive from these findings. 
First, several cases of hypocalcemia remain still unsolved and
approximately 20% of inactivating GNAS1 gene mutations are
undetected after mutation scanning with DGGE or direct se-
quencing (15). It is possible that this novel identified GNAS1
gene polymorphism plays a role in some of these cases. In a
recent report 8 new mutations of the GNAS1 gene were de-
scribed in Italian patients affected by PHP Ia (31). These sub-
jects were younger than the subjects described in the present
report (age range: 6-24 yrs vs. 7-66 yrs). It is possible to spec-
ulate that the intronic T > C polymorphism could confer the ge-
netic susceptibility to develop lower circulating Ca levels in
adulthood. An association between VDR (vitamin D receptor)
polymorphism and intestinal calcium absorption is well docu-
mented in the literature (32). However, the genetic impact of
the VDR polymorphism on calcium absorption is evidenced on-
ly in subjects with a relatively low calcium intake (32). It is inter-
esting that in the healthy population analyzed in this study the
daily calcium intake is lower than the recommended allowance
in adults (33). This condition can evidence the genetic effect of
GNAS1 gene T > C polymorphism in adulthood.
Linglart et al. (3) observed in nine informative families that pa-
tients with hormonal resistance always had a mutation on the
maternal allele and they assumed that mutations inherited from
the father, or occurring in the paternal allele, are associated
with a mild phenotype. In this study, male patient D1 developed
a mild PHP Ib in adulthood and his sons (age 15 and 17 yrs)
carried the T > C polymorphism without any clinical and bio-
chemical abnormality. On the other hand, in the patient F1 a
typical PHP Ia was detected at the age of 7 years with a T > C
polymorphism maternally transmitted. It is possible that also for
the present polymorphism, such as for other GNAS1 gene mu-
tations, the paternal imprinting of the Gsα could be an impor-
tant mechanism in the variation of phenotypic expression of the
genotype. 
In addition, Jia et al. (34) found a polymorphism at exon 5 of
the GNAS1 gene as a predictor of blood pressure, suggesting
that the GNAS1 locus may carry a functional variant that influ-
ences blood pressure variation and response to β-blockade in
essential hypertension. Similarly, the polymorphism described
in the present paper may become useful as a genetic marker
(PIC: 0.17) in predicting hypocalcemia. 
The molecular mechanisms through which the T > C polymor-
phism acts in predisposing to hypocalcemia is not yet fully elu-
cidated (11, 19). A possibility is that intronic GNAS1 gene poly-
morphism itself produces an intrinsic effect on Gsα expression
as described for other genes (35, 36). Rusin et al. (37) demon-
strated that an intronic polymorphism of the heat shock protein
70 gene was associated with a significant reduction of the re-
ceptor gene activity. Recently, a functional in vitro study on fi-
broblasts demonstrated an association between an intronic
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Table IV - Allelic distribution of the T > C polymorphism at the nu-
cleotide 433-18 of the GNAS1 gene in an Italian population of 100
unrelated individuals with no history of hypocalcemia.
Allele Total (n=100)
T 0.895
C 0.105
χ2: 1.24; p=0.35.
From Ref. 28 and 29. 
Figure 2 - Serum Ca levels in healthy subjects with various GNAS1
genotypes. Ancova analysis and LSD test showed that subjects with
CC genotype had significantly lower levels of serum Ca (p=0.04 and
p=0.03, respectively) in comparison with TT genotype.
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polymorphism of the aromatase gene and estrogen synthesis
(38). The T > C polymorphism could alter gene transcription
and protein synthesis influencing the responsiveness to PTH. It
is also possible that the T > C polymorphism could be in link-
age disequilibrium with GNAS1 gene functional polymorphisms
or alternatively with functional polymorphisms in genes neigh-
boring the GNAS1 locus (39). The functionality of the T > C
variant needs to be evaluated considering all these various hy-
potheses. 
Finally, could the identification of this GNAS1 gene polymor-
phism be used in the diagnosis and treatment of hypocalcemic
subjects without a PHP or Albright’s Hereditary Ostedystrophy
phenotype? So far three polymorphic sites have been de-
scribed in the literature for the GNAS1 gene (9, 15, 19, 27).
However, none of these has been associated with hypocal-
cemia. The data presented here support the hypothesis that
GNAS1 gene T > C polymorphism confers susceptibility for
hypocalcemia expression in adulthood. The evaluation of the
intron 5 T > C polymorphism could become useful in excluding
other causes of hypocalcemia and also in driving appropriate
interventions.
The interaction between functional polymorphisms and envi-
ronmental factors may determine both the risk of developing
diseases and the response to treatment (40). The recognition
of the pathogenetic basis of hypocalcemia and the discovery of
the polymorphisms associated with hypocalcemia could be im-
portant for patient care, making possible: a) precocious diagno-
sis of patients affected by hypocalcemia; b) prevention of com-
plications due to chronic hypocalcemia; and c) early treatment
of associated disorders. 
In conclusion, in this report we describe the segregation of a
novel GNAS1 gene polymorphism with lower levels of serum
Ca. This sequence could represent a marker allele linked to
other still unknown DNA variants of the GNAS1 gene or to oth-
er genetic loci. Further studies will attempt both to evaluate
functionality of the GNAS1 gene polymorphism and to extend
the analysis to a larger population of normal individuals.
Acknowledgements
This work was supported by grants from M.U.R.S.T. (60% and
40%), from the National Health System Projects, and from the
Ente Cassa di Risparmio di Firenze (to M.L.B.).
The Authors are grateful to Debora Strigoli for technical assis-
tance. 
References
11. Hurwitz S. Homeostatic control of plasma calcium concentration.
Crit Rev Biochem Mol Biol. 1996;31(1):41-100.
12. Carlstedt F, Lind L. Hypocalcemic syndromes. Crit Care Clin.
2001;17(1):139-53.
13. Linglart A, Carel JC, Garabedian M, Le T, Mallet E, Kottler ML.
GNAS1 lesions in pseudohypoparathyroidism Ia and Ic: genotype
phenotype relationship and evidence of the maternal transmission
of the hormonal resistance. J Clin Endocrinol Metab. 2002;87(1):
189-97.
14. Spiegel AM, Weinstein LS. Pseudohypoparathyroidism. In: Scriver
CR, Beaudet AL, Valle D, Sly WS eds. The metabolic basis of in-
herited diseases, 8th Ed. New York: McGraw-Hill. 4205-4221.
15. Takker RV. Molecular basis of PTH underexpression. In: Princi-
ples of Bone Biology. Bilezikian JP, Raisz LG and Rodan GA Eds.
Academic Press. 1996;60:837-851.
16. Thakker RV. Disorders of the calcium-sensing receptor. Biochim
Biophys Acta. 1996;10:166-70. 
17. Ding C, Deng Z, Levine MA. Analysis of GCMB gene variants in
isolated Hypoparathyroidism. J Bone Miner Res. S1-S463. 
18. Ding C, Buckingham B, Levine MA. Familial isolated hypoparathy-
roidism caused by a mutation in the gene for the transcription fac-
tor GCMB. J Clin Invest. 2001;108:1215-1220.
19. Miric A, Vechio JD, Levine M. Heterogeneous mutations in the
gene encoding the a subunit of the stimulatory G protein of adeny-
lyl cyclase in Albright Hereditary Osteodistrophy. J Clin Endocr
Metab. 1993;76:1560-1568.
10. Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations
of stimulatory G protein alpha-subunit mutations and the role of
genomic imprinting. Endocr Rev. 2001;22(5):675-705.
11. Lalande M: Imprints of disease at GNAS1. J Clin Invest. 2001;107
(7):793-794.
12. Marguet C, Mallet E, Basuyau JP, Martin D, Leroy M, Brunelle P.
Clinical and biological heterogeneity in pseudohypoparathyroidism
syndrome. Results of a multicenter study. Horm Res. 1997;48(3):
120-130.
13. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P,
Enjalbert A, Bonthron DT. Imprinting of the G(s)alpha gene
GNAS1 in the pathogenesis of acromegaly. J Clin Invest. 2001;
107(6):R31-36.
14. Spiegel AM. The molecular basis of disorders caused by defects
in G proteins. Horm Res. 1997;47(3):89-96.
15. Aldred MA, Trembath RC. Activating and inactivating mutations in
the human GNAS1 gene. Hum Mutat. 2000;16(3):183-189.
16. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L.
GTPase inhibiting mutations activate the alpha chain Gs and stim-
ulate adenylyl cyclase in human pituitary tumors. Nature. 1989;
340:692-696.
17. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E,
Spiegel AM. Activating mutations of stimulatory G protein in the
McCune-Albright syndrome. N Engl J Med. 1991;325:1688-1695.
18. Lania A, Mantovani G, Spada A. G protein mutations in endocrine
diseases. Eur J Endocrinol. 2001;145(5):543-559.
19. Bastepe M, Juppner H. Identification and characterization of two
new, highly polymorphic loci adjacent to GNAS1 on chromosome
20q13.3. Mol Cell Probes. 2000;14(4):261-264.
20. Farzel A, Bourne HR, Tahor I. The expanding spectrum of G pro-
tein disease. New Engl J Med. 1999;340:1012-1019. 
21. Hoare SR, Gardella TJ, Usdin TB. Evaluating the signal transduc-
tion mechanism of the parathyroid hormone 1 receptor. Effect of
receptor-G-protein interaction on the ligand binding mechanism
and receptor conformation. J Biol Chem. 2001;276(11):7741-
7753.
22. Neves SR, Ram PT, Iyengar R. G protein pathways. Science.
2002;296:1636-1639.
23. Mantovani G, Romoli R, Weber G, Brunelli V, De Menis E, Beccio
S, Beck-Peccoz P, Spada A. Mutational analysis of GNAS1 in pa-
tients with pseudohypoparathyroidism: identification of two novel
mutations. J Clin Endocrinol Metab. 2000;85(11):4243-4248.
24. Bastepe M, Lane AH, Juppner H. Paternal uniparental isodisomy
of chromosome 20q--and the resulting changes in GNAS1 methy-
lation-as a plausible cause of pseudohypoparathyroidism. Am J
Hum Genet. 2001;68(5):1283-1289.
25. Juppner H, Schipani E, Bastepe M, Cole DE, Lawson ML,
Mannstadt M, Hendy GN, Plotkin H, Koshiyama H, Koh T, Craw-
ford JD, Olsen BR, Vikkula M. The gene responsible for pseudo-
hypoparathyroidism type Ib is paternally imprinted and maps in
four unrelated kindreds to chromosome 20q13.3. Proc Natl Acad
Sci U S A. 1998;95(20):11798-11803.
26. Fisher JA, Egert F, Werder E, Born W. An inherited mutation asso-
ciated with functional deficiency of the alpha-subunit of the gua-
nine nucleotide-binding protein Gs in pseudo and pseudo-pseudo-
hypoparatiroidism. Clin Endocr Metab. 1998;83:935-938.
27. Waltman C, Levine MA, Schwindinger F, Wand GS. Polymorphism
of the gene encoding the alpha subunit of the stimulatory G-pro-
tein of adenylyl cyclase (GNAS1). Hum Genet. 1994;93:477-478. 
28. Hartl DL, Clark AG. Principles of population genetics. Sinaver Ass.
Inc. Third Ed. 3:71-109.
29. Li CC. First Course in Population Genetics The Boxwood Press,
Pacific Grove, California. 1976:1-13.
30. Skolinck MH, White R. Strategies for detecting and characterizing
144 Clinical Cases in Mineral and Bone Metabolism 2007; 4(2): 139-145
L. Masi et al.
restriction fragment length polymorphisms (RFLP’s). Cytogenet
Cell Genet. 1982;32:58-62.
31. De Sanctis L, Romagnolo D, Oliviero M, Buzi F, Maghnie M, Scirè
G, Crinò A, Baroncelli G, Salerno M, Di Maio S, Cappa M, Grosso
S, Rigon F, Lala R, De Sanctis C, Dianzini I. Molecular analysis of
the GNAS1 gene for the correct diagnosis of Albright Hereditary
Osteodystrophy and Pseudohypoparathyraoidism. Pediatric Res.
2003;53:749-755.
32. Gennari L, Becherini L, Masi L, Gonnelli S, Cepollaro C, Martini S,
Mansani R, Brandi ML. Vitamin D receptor genotypes and intesti-
nal calcium absorption in postmenopausal women. Calcified Tis-
sue International. 1997;61:460-463.
33. Human Vitamin and Mineral Requirements World Health Organi-
zation Food and Agricolture Organization of the United Nations.
2002 Rome.
34. Jia H, Hingorani AD, Sharma P, Hopper R, Dicherson C, Trutwein D,
Lloyd DD, Brown MJ. Association of the Gsα gene with essential hy-
pertension and response to β-blockade. Hypertension. 1999;34:8-14.
35. Fu Y-H, Kuhl DPA, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S,
Verkerk AJMH, Holden JJA, Fenwick RGJ, Warren ST, Nelson
DL, Caskey CT. Variation of the CGG repeat at the fragile X site.
Results in genetic instability: resolution of the Sherman Paradox.
Cell. 1991;67:1047-1058. 
36. Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, Pizzuti
A, Reiner O, Richards S, Victoria MF, Zhang F, Eussen BE, van
Ommen BJB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB,
Galiaard H, Caskey T, Nelson DL, Oostra BA, Warren ST. Identifi-
cation of a gene (FMR-1) containing CGG repeat coincident with a
breakpoint cluster region exhibiting length variation in fragile X
syndrome. Cell. 1991;65:905-907.
37. Rusin M, Zientek H, Krzesniak M, Mausecka E, Zborek A, Gruca
S, Butkiewicz D, Vaitiekunaite R, Lisowska K, Gzybowska E,
Krawczy Z. Intronic polymorphysm (1541-1542 del GT) of the con-
stitutive heat shock protein 70 gene has functional significance
and shows evidence of association with lung cancer risk. Mol Car-
cinogenesis. 2004;39:155-163.
38. Gennari L, Masi L, Merlotti D, Picariello L, Gonnelli S, Falchetti A,
Lucani B, Gennari C, Brandi ML. A polymorphic CYP19 TTTA re-
peat influences aromatase activity and estrogen in elderly men: ef-
fects on bone loss and fracture risk. J Clin Endocrinol Metab.
2004; 89:2803-2810.
39. Bastepe M, Juppner H. Identification and characterization of two
new, highly polymorphic loci in adjacent to GNAS1 on chromo-
some 20q13. Mol Cell Probes. 2000;14:261-264.
40. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, John-
son JA. Impact of genetic polymorphism of the β2-adrenergic re-
ceptor on albuterol bronchodilator pharmacodynamics. Clin Phar-
macol Ther. 1999;65:519-525.
Clinical Cases in Mineral and Bone Metabolism 2007; 4(2): 139-145 145
A novel polymorphism at the GNAS1 gene
